Acute Coronary Syndrome Market Analysis, Epidemiology, and Forecast

DelveInsight's comprehensive "Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast-2034" analysis delivers extensive understanding of Acute Coronary Syndrome, historical and projected epidemiology alongside market trends across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Explore Acute Coronary Syndrome market patterns, treatment landscapes, and emerging therapeutic agents shaping the future. Access sample analysis @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Major Highlights from the Acute Coronary Syndrome Market Analysis

• During December 2025, Novartis Pharmaceuticals performed a clinical investigation to learn about the effects of inclisiran in individuals with serious heart conditions (acute coronary syndromes), when this treatment is initiated early after hospital admission. To accomplish this, researchers will assess the effects of inclisiran compared to placebo, when administered with standard treatment.

• During December 2025, Janssen Research & Development LLC launched a study to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).

• The total incident cases of ACS in the United States is estimated to be approximately 1.3 million in 2024. The cases are projected to increase by 2034.

• In EU4 and the UK, the incident cases of ACS were approximately 515,400 cases in males and approximately 270,200 cases in females in 2024.

• There were approximately 46,400 cases of STEMI and approximately 35,000 cases of NSTEMI in Japan in 2024.

• Leading Acute Coronary Syndrome pharmaceutical organizations include Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, among others.

• Notable Acute Coronary Syndrome investigational agents include LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), among others.

Strategize your business objectives by comprehending market dynamics @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Acute Coronary Syndrome Disease Background

Acute Coronary Syndrome (ACS) represents a medical emergency that encompasses a spectrum of conditions caused by a sudden reduction or complete blockage of blood flow to the heart muscle, most commonly resulting from rupture of an atherosclerotic plaque and subsequent thrombus formation in the coronary arteries. It encompasses unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), which differ in severity and extent of myocardial damage.

Acute Coronary Syndrome Epidemiology Analysis

• Total Incident Cases of ACS

• Type-specific Incidence of ACS

• Type-specific Incidence of AMI

• Gender-specific Incidence of ACS

Access additional information about Acute Coronary Syndrome Prevalence @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Acute Coronary Syndrome Commercialized Therapeutic Agents

LODOCO (colchicine): AGEPHA Pharma

Colchicine, an anti-inflammatory alkaloid, has assumed a significant function in the management of cardiovascular inflammation following its first medicinal use in ancient Egypt. Primarily utilized in high doses for managing acute gout flares during the 20th century, research in the early 21st century revealed that low-dose colchicine effectively manages acute gout attacks, diminishes the risk of recurrent pericarditis, and can contribute to secondary prevention of major adverse cardiovascular events. As the first FDA-authorized targeted anti-inflammatory cardiovascular therapy, colchicine currently maintains a unique function in the management of atherosclerotic cardiovascular disease.

REPATHA (evolocumab): Amgen

REPATHA represents a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Over the past decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. During December 2017, the US FDA authorized REPATHA to prevent heart attacks, strokes, and coronary revascularizations in adults with established cardiovascular disease. Subsequently in May 2018, the European Commission also authorized a new indication in the REPATHA label for adults diagnosed with established atherosclerotic cardiovascular disease (myocardial infarction, stroke, or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) concentrations.

Acute Coronary Syndrome Investigational Therapeutic Agents

FDY-5301: Faraday Pharmaceuticals

FDY-5301 represents a patented elemental reducing agent containing sodium iodide. It operates to catalytically destroy hydrogen peroxide, which is generated as a response to acute injury and contributes to loss of muscle mass and function. Preclinical investigations of FDY-5301 have demonstrated its ability to reduce cardiac and skeletal muscle injury. Phase I data have demonstrated no signs of toxicity in healthy subjects. A Phase II trial of FDY-5301 in managing reperfusion injury following STEMI demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage.

Dutogliptin: Recardio

Dutogliptin (REC-01), developed by Recardio, represents a potent and selective DPP4 inhibitor. Dutogliptin is administered via SC injection; the protein belongs to the class of enzyme inhibitors called gliptins or DPP-IV inhibitors. The combination of G-CSF with dutogliptin substantially enhanced survival and reduced infarct size in the preclinical model. Once the diagnosis of AMI is confirmed and percutaneous intervention and stent implantation are completed, the patient receives or can self-administer daily SC injection of dutogliptin for 2 weeks in co-administration with G-CSF for 5 days. Recardio has received FDA and EMA clearance for a global pivotal Phase III clinical investigation in acute myocardial infarction. The trial is planned to initiate in 2025 and serve as the basis to apply for market authorization in major global markets.

Acute Coronary Syndrome Drug Adoption and Pipeline Activities

The drug adoption segment concentrates on the uptake velocity of potential therapeutic agents recently introduced in the Acute Coronary Syndrome marketplace or anticipated to launch during the analysis period. The evaluation encompasses Acute Coronary Syndrome market adoption by drugs, patient adoption by treatment modalities, and revenue of individual drugs. Furthermore, the therapeutics evaluation segment facilitates understanding of drugs demonstrating the most accelerated adoption and underlying reasons for maximal utilization. Additionally, it compares therapeutic agents based on market penetration. The analysis also encompasses the Acute Coronary Syndrome Pipeline Development Activities. It delivers valuable insights regarding various therapeutic candidates across multiple phases and primary organizations engaged in developing targeted therapies. It additionally analyzes recent advancements including collaborations, acquisitions, mergers, licensing patent information, and other intelligence for emerging therapeutic agents.

For additional information, access Acute Coronary Syndrome Medication and Companies @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Acute Coronary Syndrome Commercialized Therapeutic Agents

• LODOCO (colchicine): AGEPHA Pharma

• REPATHA (evolocumab): Amgen

Acute Coronary Syndrome Investigational Therapeutic Agents

• Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche

• Dutogliptin: Recardio

Coverage of the Acute Coronary Syndrome Market Analysis

• Analysis Period: 2020-2034

• Coverage: 7MM

• Acute Coronary Syndrome Pharmaceutical Organizations: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, among others

• Acute Coronary Syndrome Therapeutic Agents: LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), among others

• Acute Coronary Syndrome Therapeutic Evaluation: Acute Coronary Syndrome current commercialized and Acute Coronary Syndrome investigational therapies

• Acute Coronary Syndrome Market Dynamics: Acute Coronary Syndrome market growth factors and Acute Coronary Syndrome market obstacles

• Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry methodologies

• Acute Coronary Syndrome Unmet Requirements, KOL perspectives, Analyst perspectives, Acute Coronary Syndrome Market Access and Reimbursement

Do you know the treatment paradigms for various countries? Access our Acute Coronary Syndrome Treatment Market @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Report Structure

1. Acute Coronary Syndrome Market Analysis Introduction

2. Executive Summary for Acute Coronary Syndrome

3. SWOT evaluation of Acute Coronary Syndrome

4. Acute Coronary Syndrome Patient Distribution (%) Overview at a Glance

5. Acute Coronary Syndrome Market Overview at a Glance

6. Acute Coronary Syndrome Disease Background and Overview

7. Acute Coronary Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Coronary Syndrome

9. Acute Coronary Syndrome Current Treatment and Medical Practices

10. Acute Coronary Syndrome Unmet Requirements

11. Acute Coronary Syndrome Emerging Therapeutic Agents

12. Acute Coronary Syndrome Market Perspective

13. Country-Wise Acute Coronary Syndrome Market Evaluation (2020-2034)

14. Acute Coronary Syndrome Market Access and Reimbursement of Therapeutic Agents

15. Acute Coronary Syndrome Market Growth Factors

16. Acute Coronary Syndrome Market Obstacles

17. Acute Coronary Syndrome Appendix

18. Acute Coronary Syndrome Analysis Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a prominent healthcare-focused market research and consulting organization that delivers clients with premium market intelligence and analysis to facilitate informed business decisions. With a team of seasoned industry specialists and comprehensive understanding of the life sciences and healthcare industries, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain a competitive advantage.

Contact Us 

Kanishk

kkumar@delveinsight.com